Post

New research · Ophthalmology
Ocular immunology and inflammation · 14h
StudyOcular immunology and inflammation · 2026

Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis.

Jiantong Du, Chen Xing, Zonghui Ma, Zhiyue Zhang
Read paper
OphthalmologyStudy

Brolucizumab shows a massive reporting signal for retinal vasculitis versus other anti-VEGF agents.

Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis.

Jiantong Du … Zhiyue Zhang
Ocular immunology and inflammation · 2026
Background

The safety profiles of high-dose intravitreal anti-vascular endothelial growth factor (VEGF) agents remain incompletely characterized.

Purpose

This study aimed to compare ocular adverse events, especially intraocular inflammation, associated with brolucizumab, faricimab, and 8 mg aflibercept.

Methods

Adverse event reports for high-dose anti-VEGF agents were extracted from the FDA Adverse Event Reporting System (FDA Adverse Event Reporting System) database.

n = 8,470 reports
Results
ROR = 7,451.51
Reporting odds ratio measures signal strength; higher values mean much more frequently reported than expected.
n = 8,470 reports
More results

Among 8,470 reports where high-dose anti-VEGF agents were designated as primary suspects, intraocular inflammation (intraocular inflammation) was the primary adverse reaction.

“
Conclusion

Intraocular inflammation profiles differ significantly among high-dose anti-VEGF agents. Comprehensive evaluation of individual patients' risk factors is recommended to guide clinical decision-making.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment